What Are The Risk Factors For Organon & Co. (OGN)?

As of Friday close, Organon & Co.’s (NYSE:OGN) stock was down -$0.91, moving down -2.81 percent to $31.50. The average number of shares traded per day over the past five days has been 1,908,060 shares. 4 times new highs have been achieved over the past 5 days, with a -$0.22 fall in that time frame. In the last twenty days, the average volume was 1,535,115, while in the previous 50 days, it was 1,467,426.

Since last month, OGN stock retreated -4.69%. Shares of the company fell to $31.06 on 07/18/22, the lowest level in the past month. A 52-week high of $39.47 was reached on 03/02/22 after having rallying from a 52-week low of $28.50. Since the beginning of this year, OGN’s stock price has risen by 3.45% or $1.05, and marked a new high 23 times. However, the stock has declined by -20.20% since its 52-week high.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Organon & Co. (OGN) last reported insider trading activity 352 days ago on Aug 19. Francisco Ma. Fatima, the Director of the company, purchased of 3,000 shares for $33.79 on Aug 19. It resulted in a $101,370 investment by the insider.

Valuation Metrics

The latest dividend of $0.28 per share was paid out, remained unchanged from last year’s $0.28.

Financial Health

In the three months ended March 30, Organon & Co.’s quick ratio stood at 1.20, while its current ratio was 1.60, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 63.00% percent. In the year ended March 30, operating margins totaled 23.60%. Based on annual data, OGN earned $3.92 billion in gross profit and brought in $6.3 billion in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 17.70%. Return on equity (ROE) for the past 12 months was -82.40%.

In Organon & Co.’s quarter-end financial report for March 30, it reported total debt of $9.09 billion. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. OGN’s revenue rose 3.89% to $1.6 billion during the quarter, while net income inched up to $1.57 billion. While analysts expected Organon & Co. to report $1.3 quarterly earnings, the actual figure was $1.65 per share, beating the consensus estimate by 26.90%. During the quarter, the company generated $495.0 million in EBITDA. The liabilities of Organon & Co. were 11.85 billion at the end of its most recent quarter ended March 30. The value of shareholders’ equity is $253.64 million.

Technical Picture

This quick technical analysis looks at Organon & Co.’s (OGN) price momentum. With a historical volatility rate of 22.84%, the RSI 9-day stood at 37.96% on 05 August.

With respect to its five-day moving average, the current Organon & Co. price is down by -0.69% percent or -$0.22. At present, OGN shares trade -3.82% below its 20-day simple moving average and -2.66% percent below its 100-day simple moving average. However, the stock is currently trading approximately -16.04% below its SMA50 and -10.15% below its SMA200.

Stochastic coefficient K was 50.10% and Stochastic coefficient D was 50.76%, while ATR was 0.95. Given the Stochastic reading of 16.67% for the 14-day period, the RSI (14) reading has been calculated as 39.42%. As of today, the MACD Oscillator reading stands at -0.04, while the 14-day reading stands at 0.05.

Analyst Ratings

Organon & Co. downgraded its rating on Organon & Co. (NYSE: OGN) to a Neutral in a note to investors on August 05, 2022. The analysts firm previously had a Buy rating on the stock.Organon & Co. (OGN) has been rated Overweight by analysts. According to 0 brokerage firms, OGN is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Organon & Co. stock as buy, with 3 recommending it as overweight.

With a median target price of $37.00, the current consensus forecast for the stock is $35.00 – $41.00. Based on these forecasts, analysts predict Organon & Co. (OGN) will achieve an average price target of $37.86.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]